Drugs / HIV-1 gp 160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00122564 | Jun 2003 → Apr 2005 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 gp 160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00122564 ↗ |
| Modality | Vaccine | “prophylactic HIV vaccine” NCT00122564 ↗ |
| Route | Intranasal | “Administered by Transmucosal (Nasal or Vaginal) Routes” NCT00122564 ↗ |